Pharmacokinetics
| |
Evaluation of Impaired Renal Function on Lamivudine Pharmacokinetics.
Bouazza N, Tréluyer JM, Ghosn J,
et
al
Br J Clin Pharmacol.
2014 Apr 21
Abstract
Pharmacokinetic Modelling of Efavirenz, Atazanavir,
Lamivudine and Tenofovir in the Female Genital Tract of
HIV-Infected Pre-Menopausal Women.
Dumond JB,
Nicol MR, Kendrick RN, et al
Clin
Pharmacokinet. 2012 Oct 9
Abstract
Pharmacokinetics of Lamivudine, Zidovudine, and Nevirapine
Administered as a
Fixed-Dose
Combination Formulation Versus Coadministration of the Individual
Products.
Marier JF, Dimarco M, Guilbaud R, et al
J Clin Pharmacol. 2007 Nov;47(11):1381-1389.
Abstract
|
FULL-TEXT ARTICLE
Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency
Virus-
Infected
Patients Enrolled in Two Phase III Clinical Trials
Moore KH, Yuen GJ, Hussey EK, et al.
Antimicrob. Agents Chemother. 1999 43: 3025-3029.
Paper |
Resistance
| |
The combination of the R263K and M184I/V resistance
substitutions against dolutegravir and lamivudine decreases HIV
replicative capacity.
Singhroy DN, Wainberg
MA, Mesplède T.
Antimicrob Agents Chemother.
2015 Feb 9.
Abstract
An integrated molecular dynamics, principal component
analysis and residue interaction network approach reveals the impact of
M184V mutation on HIV reverse transcriptase resistance to lamivudine.
Bhakat S, Martin AJ, Soliman ME.
Mol Biosyst. 2014 Jun
16
Abstract
FULL-TEXT ARTICLE
Virological Outcomes and Drug Resistance in Chinese Patients after 12
Months of 3TC-Based First-Line Antiretroviral Treatment, 2011-2012.
Wang J, He C, Hsi JH, et al
PLoS One.
2014 Feb 7;9(2):e88305
Paper
Interaction of reverse transcriptase (RT) mutations conferring resistance
to lamivudine and etravirine:
effects on fitness and RT activity of human immunodeficiency virus type 1.
Hu Z, Kuritzkes DR.
J Virol.
2011 Aug 17.
Abstract
A comparison of the phenotypic susceptibility profiles of
emtricitabine and lamivudine.
Borroto-Esoda K, Parkin N, Miller MD.
Antivir Chem Chemother.
2007;18(5):297-300.
Abstract
|
Limited development and progression of resistance of HIV-1 to the nucleoside
analogue reverse
transcriptase inhibitor lamivudine in human primary macrophages.
Aquaro S, Svicher V, Ceccherini-Silberstein F, et al|
J Antimicrob Chemother. 2005 Apr 21;
Abstract
|
| Diagnostics |
| |
| |
A micellar liquid chromatography method for the quantification of abacavir,
lamivudine and raltegravir in plasma.
Peris-Vicente J, Villareal-Traver M, Casas-Breva I,
et
al
J Pharm Biomed Anal.
2014 Jun 13;98C:351-355.
Abstract
Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine
concentration in plasma
of HIV-infected patients by HPLC-MS/MS.
Notari S, Sergi M, Montesano C,
Ivanovic J, et al
IUBMB Life.
2012 Apr 4.
Abstract |
Selective Determination of Antiretroviral Agents Tenofovir, Emtricitabine,
and Lamivudine in Human
Plasma by a LC-MS-MS Method for a Bioequivalence Study in Healthy Indian
Subjects.
Yadav M, Singhal P, Goswami S, et
al
J Chromatogr Sci. 2010;48(9):704-13.
Abstract |
Adverse Events
|
| |
Lamivudine-associated macrocytosis in HIV-infected patients.
Khawcharoenporn T, Shikuma CM, Williams AE, Chow DC.
Int J STD AIDS. 2007
Jan;18(1):39-40.
Abstract
|
Efficacy
| |
Lamivudine plus a boosted-protease inhibitor as simplification
strategy in HIV-infected patients with toxicity to nucleoside analogues.
Casado J, De la Calle C, Del Palacio M,
et al
J Int AIDS Soc. 2012 Nov
11;15(6):18382.
Abstract
Lamivudine Plus a Boosted-Protease Inhibitor as Simplification
Strategy in HIV-Infected Patients: Proof of Concept.
Casado JL, de la Calle C, Del
Palacio M,
et al
AIDS Res Hum Retroviruses.
2012 Nov 19.
Abstract
Once-Daily versus Twice-Daily Lamivudine, in Combination with
Zidovudine and Efavirenz,
for the Treatment of Antiretroviral-Naive Adults with HIV
Infection: A Randomized
Equivalence
Trial.
DeJesus E, McCarty D, Farthing CF
Clin Infect Dis. 2004 Aug 1;39(3):411-8.
Abstract
|
Relative Anti-HIV-1 Efficacy of Lamivudine and
Emtricitabine In Vitro Is
Dependent on
Cell Type.
Hazen R, Lanier ER.
J Acquir Immune Defic Syndr
2003 Mar 1;32(3):255-
Abstract
Lamivudine
Can Exert a Modest Antiviral Effect against Human
Immunodeficiency Virus
Type 1 Containing theM184V Mutation.
Quan Y, Brenner BG, Oliveira M, Wainberg MA
Antimicrob Agents Chemother 2003 Feb;47(2):747-54
Abstract
Lamivudine 300 mg QD versus continued lamivudine 150
mg BID with stavudine and
a
protease inhibitor in suppressed patients.
Sension MG, Bellos NC, Johnson J, et al.
HIV Clin Trials 2002 Sep-Oct;3(5):361-70
Abstract
Nevirapine or Lamivudine plus Stavudine and Indinavir: Examples of 2-Class
versus
3-Class
Regimens for the Treatment of Human Immunodeficiency Virus Type 1.
Launay O,
Gerard L, Morand-Joubert L
Clin Infect Dis 2002 Nov 1;35(9):1096-105
Abstract
|
| |
Lamivudine monotherapy-based cART is efficacious for HBV treatment in
HIV/HBV co-infection when baseline
HBV DNA<20,000IU/ml.
Li Y, Xie J, Han Y,
et al
J Acquir Immune Defic Syndr.
2016 Jan 7
Abstract
Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and
rate and pattern of lamivudine-resistant HBV infection in patients receiving
antiretroviral therapy.
Calisti G, Muhindo R, Boum Y2, et al
Trans R Soc Trop Med Hyg. 2015 Sep
18.
Abstract
High incidence of lamivudine-resistance associated vaccine-escape
HBV mutant among HIV-coinfected patients on prolonged antiretroviral therapy.
Pal A, Sarkar N, Saha D, et al
Antivir
Ther. 2015 Feb 5
Abstract
FULL-TEXT PDF
ARTICLE
Emergence
of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The
Gambia, West Africa.
Stewart B, Jobarteh ML, Sarge-Njie R,
et al
BMC Res Notes. 2011 Dec
23;4(1):561
Paper
Hepatitis B virus genotype distribution and its lamivudine-resistant
mutants in HIV-coinfected
patients with chronic and occult hepatitis B.
Quarleri J, Moretti F, Bouzas MB, et al
AIDS Res Hum Retroviruses. 2007
Apr;23(4):525-31.
Abstract |
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected
patients:
factors associated with response.
Jain MK, Comanor L, White C, et al
J Viral Hepat. 2007 Mar;14(3):176-82.
Abstract |
 |
General
Reports
HBV
Infection/Disease
Main
New/Newsworthy
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader